<SEC-DOCUMENT>0001104659-23-054337.txt : 20230501
<SEC-HEADER>0001104659-23-054337.hdr.sgml : 20230501
<ACCEPTANCE-DATETIME>20230501160536
ACCESSION NUMBER:		0001104659-23-054337
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230501
DATE AS OF CHANGE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioXcel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001720893
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				821386754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38410
		FILM NUMBER:		23873547

	BUSINESS ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-643-8060

	MAIL ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>tm2313834d1_10ka.htm
<DESCRIPTION>FORM 10-K/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:BTAI="http://bioxceltherapeutics.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_BTAI_bioxceltherapeutics.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001720893 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div></div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>



<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM <span id="xdx_908_edei--DocumentType_c20220101__20221231_z94McUcVah1i"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K/A</ix:nonNumeric></span></p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Amendment No.&#160;1)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>(Mark one)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Wingdings"><b><span id="xdx_90F_edei--DocumentAnnualReport_c20220101__20221231_zCSikTEuXxsd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#120;</ix:nonNumeric></span>
</b></span><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Annual Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange
Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the year ended
<span id="xdx_90A_edei--DocumentPeriodEndDate_c20220101__20221231_zfEiWaBQuza4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>or</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Wingdings"><b><span style="font-family: Wingdings"><span id="xdx_901_edei--DocumentTransitionReport_c20220101__20221231_zqaTvF5EUsAe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#168;</ix:nonNumeric></span></span>
</b></span><b> &#160;&#160;&#160;&#160;&#160;&#160;&#160;Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange
Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number <span id="xdx_907_edei--EntityFileNumber_c20220101__20221231_zkX95ULVzPd2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-38410</ix:nonNumeric></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--EntityRegistrantName_c20220101__20221231_zwuU05yPci42"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">BioXcel Therapeutics, Inc.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zHDTQLUb7tna"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation or
    organization)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td style="width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20220101__20221231_zO9EH5Z7dB4b"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">82-1386754</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S.&#160;Employer Identification No.)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20220101__20221231_zXbzIWakDDA2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">555 Long Wharf Drive</ix:nonNumeric></span><br />
    <span id="xdx_90A_edei--EntityAddressCityOrTown_c20220101__20221231_zBP6XQFUt3C3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">New Haven</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20220101__20221231_ztEt8MXXlyEc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">CT</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)&#160;</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20220101__20221231_z5SFa697bQuf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">06511</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90C_edei--CityAreaCode_c20220101__20221231_zRmfHVranD2d"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">475</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20220101__20221231_z7yqPGhUUxva"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">238-6837</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 33%; padding-top: 10pt; text-align: center; font-size: 10pt"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="vertical-align: top; width: 32%; padding-top: 10pt; text-align: center; font-size: 10pt"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="vertical-align: top; width: 35%; padding-top: 10pt; text-align: center; font-size: 10pt"><span style="font-size: 10pt">Name of exchange on which registered</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center; font-size: 10pt"><b><span id="xdx_905_edei--Security12bTitle_c20220101__20221231_zs7CHa0eaxPh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><b><span id="xdx_90D_edei--TradingSymbol_c20220101__20221231_zKMRMRYddyj6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">BTAI</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center; font-size: 10pt"><b><span id="xdx_904_edei--SecurityExchangeName_c20220101__20221231_zbhCC9N42bEa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section&#160;12(g)
of the Act: <b>None</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Wingdings; font-size: 10pt">&#168;</span>
<span id="xdx_905_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_z41qowDg9Ini"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Wingdings; font-size: 10pt">&#120;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes <span style="font-family: Wingdings; font-size: 10pt">&#168;</span>
<span id="xdx_90C_edei--EntityVoluntaryFilers_c20220101__20221231_zYy0rGGkBBa2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Wingdings; font-size: 10pt">&#120;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant: (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has
been subject to such filing requirements for the past 90 days. <span id="xdx_908_edei--EntityCurrentReportingStatus_c20220101__20221231_zn8M7uf59Zad"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Wingdings; font-size: 10pt">&#120;</span>
No <span style="font-family: Wingdings; font-size: 10pt">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit
such files). <span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20220101__20221231_zujTnJt7th64"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Wingdings; font-size: 10pt">&#120;</span>
No <span style="font-family: Wingdings; font-size: 10pt">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26%; text-align: left; font-size: 10pt">Large accelerated filer  <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings">&#168;</span> </span></td>
    <td style="width: 21%; text-align: left; font-size: 10pt">Accelerated filer  <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings">&#168;</span> </span></td>
    <td style="width: 24%; text-align: left; font-size: 10pt"><span id="xdx_906_edei--EntityFilerCategory_c20220101__20221231_zbkeczM3gF3k"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span>  <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings">&#120;</span> </span></td>
    <td style="width: 29%; text-align: left; font-size: 10pt">Smaller reporting company  <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--EntitySmallBusiness_c20220101__20221231_z62rLi9TzXDd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#120;</ix:nonNumeric></span></span> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">Emerging growth company  <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20220101__20221231_zyEkFMdaxdPf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <span style="font-family: Wingdings; font-size: 10pt"><span id="xdx_90B_edei--EntityExTransitionPeriod_c20220101__20221231_zMkxxc0yz9V6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. <span style="font-family: Wingdings; font-size: 10pt"><span id="xdx_90B_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zCTTLQXjx9B6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities are registered
pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the
filing reflect the correction of an error to previously issued financial statements. <span style="font-family: Wingdings; font-size: 10pt">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of
the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Wingdings; font-size: 10pt">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings">&#168;</span></span>
<span id="xdx_90F_edei--EntityShellCompany_c20220101__20221231_zDLbPzaCvFul"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Wingdings; font-size: 10pt"><span style="font-family: Wingdings">&#120;</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June&#160;30, 2022,
the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s
common stock held by non-affiliates of the registrant was approximately $<span id="xdx_90B_edei--EntityPublicFloat_iI_c20220630_zDLr8uUxNpTi"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,888,981</ix:nonFraction></span> (based upon the closing sale price of the registrant&#8217;s
common stock reported on the Nasdaq Capital Market on that date). This calculation excludes shares held by the registrant&#8217;s current
directors and executive officers and stockholders that the registrant has concluded are affiliates of the registrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were <span id="xdx_90E_edei--EntityCommonStockSharesOutstanding_iI_pdp0_c20230313_zdreJjowaied"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-13" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">29,009,536</ix:nonFraction></span> shares
of our common stock outstanding at March&#160;13, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor Name</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor Location</span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor Firm ID</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AuditorName_c20220101__20221231_ziNbaKF0VbYb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Ernst &amp; Young LLP</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--AuditorLocation_c20220101__20221231_z3J1vSt3uwz5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Stamford, Connecticut</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorFirmId_c20220101__20221231_zu7A2tTsbBol"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">42</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXPLANATORY NOTE</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March&#160;16, 2023, BioXcel
Therapeutics, Inc. filed its <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1720893/000155837023003940/btai-20221231x10k.htm" style="-sec-extract: exhibit">Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022</a> (&#8220;Original Form 10-K&#8221;).
The Original Form 10-K omitted portions of Part III, Items&#160;10 (Directors, Executive Officers and Corporate Governance), 11 (Executive
Compensation), 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), 13 (Certain Relationships
and Related Transactions, and Director Independence), and 14 (Principal Accountant Fees and Services) in reliance on General Instruction
G(3) to Form 10-K, which provides that such information may be either incorporated by reference from the registrant&#8217;s definitive
proxy statement or included in an amendment to Form 10-K, in either case filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
not later than 120 days after the end of the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We no longer expect that the
definitive proxy statement for our 2023 annual meeting of stockholders will be filed within 120 days of December&#160;31, 2022. Accordingly,
this Amendment No.&#160;1 to Form 10-K (&#8220;Amendment&#8221;) is being filed solely to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">amend and restate Part III, Items 10, 11, 12, 13, and 14 of the Original Form 10-K to include the information
required by such Items;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">delete the reference on the cover of the Original Form 10-K to the incorporation by reference of portions
of our proxy statement into Part III of the Original Form 10-K; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">file new certifications of our principal executive officer and principal financial officer as exhibits
to this Amendment under Item 15 of Part IV hereof, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (&#8220;Exchange
Act&#8221;). Because no financial statements are contained within this Amendment, we are not including certifications pursuant to Section&#160;906
of The Sarbanes-Oxley Act of 2002.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment does not otherwise
change or update any of the disclosures set forth in the Original Form 10-K and does not otherwise reflect any events occurring after
the filing of the Original Form 10-K. Accordingly, the Amendment should be read in conjunction with the Original Form 10-K and the Company&#8217;s
filings made with the SEC subsequent to the filing of the Original Form 10-K. Capitalized terms used herein and not otherwise defined
are defined as set forth in the Original Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Annual Report
on Form 10-K, unless otherwise specified or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221;
the &#8220;Company&#8221; or &#8220;BTI&#8221; refer to BioXcel Therapeutics, Inc., and &#8220;BioXcel, LLC&#8221; refers to the Company&#8217;s
former parent company and significant stockholder, BioXcel LLC, and its predecessor, BioXcel Corporation. All brand names or trademarks
appearing in this Annual Report on Form 10-K are the property of their respective owners, including IGALMI, which is a trademark of BioXcel
Therapeutics, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Page</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left"><a href="#ss001">PART III</a></td>
    <td style="width: 10%; text-align: right"><a href="#ss001">1</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="padding-left: 0.5in; text-align: left"><a href="#ss002">Item 10. Directors, Executive Officers, and Corporate Governance.</a></td>
    <td style="text-align: right"><a href="#ss002">1</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-align: left"><a href="#ss003">Item 11. Executive Compensation</a></td>
    <td style="text-align: right"><a href="#ss003">4</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-indent: -0.5in; padding-left: 1in; text-align: left"><a href="#ss004">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder &#160;Matters</a></td>
    <td style="text-align: right"><a href="#ss004">9</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-align: left"><a href="#ss005">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></td>
    <td style="text-align: right"><a href="#ss005">11</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="padding-left: 0.5in; text-align: left"><a href="#ss006">Item 14. Principal Accounting Fees and Services</a></td>
    <td style="text-align: right"><a href="#ss006">13</a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-align: left"><a href="#bb1">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></td>
    <td style="text-align: right"><a href="#bb1">14</a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><span id="ss001"></span>PART
III</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span id="ss002"></span>Item 10.</td><td style="text-align: left">Directors, Executive Officers, and Corporate Governance.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
with respect to our Board of Directors (the &#8220;Board&#8221;) is presented as of May 1,&#160;2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Peter Mueller, Ph.D.</i></b>,
67, has served as a director of the Company since April&#160;2017 and Chairman of the Board since August&#160;2017. With over 30 years
of global pharma and biotech experience, Dr.&#160;Mueller is currently the President of the Mueller Health Foundation, a private foundation
tackling globally lethal infectious diseases such as tuberculosis by addressing latency and the ever-growing challenges of antimicrobial
resistance. From 2014 to 2016, he was President of R&amp;D and Chief Scientific Officer of Axcella Health, a biotechnology company. From
2003 to 2014, Dr.&#160;Mueller served as Executive Vice President Global Research and Development &amp; Chief Scientific Officer for Vertex
Pharmaceuticals, Incorporated, a biotechnology company. He was involved in the development of Incivek (2011), Kalydeco (2012), and Orkambi
(2014). Prior to his tenure at Vertex, he served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals,
Inc. overseeing global research programs (immunology, inflammation, cardiovascular diseases and gene therapy) and the development of all
drug candidates of the company&#8217;s worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He was involved
in the development of Spiriva, Combivent, Atrovent and Viramune. Dr.&#160;Mueller received both an undergraduate degree and a Ph.D. in
Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He
completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. He is a member of various
scientific and political societies and currently serves on the Board of the US-India Chamber of Commerce Biotech. He also services as
chairman of the Scientific Advisory Board of BioXcel LLC and is an advisor to the University of Iowa Center for Bioanalysis and Bioprocessing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>June Bray</i></b>, 69,
has served as a director of the Company since March&#160;2021. She previously served as Senior Vice President, Global Regulatory Affairs
and Medical Writing of Allergan, Inc., a pharmaceutical company, from 2008 to 2020, where she was in charge of global regulatory strategies
for development projects and lifecycle management for all therapeutic areas. From 2006 to 2008, Ms. Bray was Vice President, Regulatory
Affairs at Organon &amp; Co. (prior to its merger with Merck &amp; Co.), where she led departments responsible for regulatory activities
for development and marketed products and, from 1980 to 2006, Ms. Bray served in various capacities at Berlex Laboratories, Inc., most
recently as Vice President, Global Regulatory Affairs for Specialized Therapeutics/Oncology, a position she held from 2003 to 2006. Ms.
Bray has served on the Board of Quince Therapeutics, Inc. since June&#160;2022. Ms. Bray holds an M.B.A. from Fairleigh Dickinson University
and a B.S.&#160;from the University of Rhode Island.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sandeep Laumas, M.D.</i></b>,
55, has served as a director of the Company since September&#160;2017. Since June&#160;2020, Dr.&#160;Laumas has served as Chief Business
Officer and Chief Financial Officer of Instil Bio Inc. He served as a Director of BioXcel Corporation from May&#160;2013 to August&#160;2017.
Dr.&#160;Laumas served as a director of 9 Meters BioPharma, Inc. (formerly Innovate Biopharmaceuticals Inc.), a biopharma company, from
January&#160;2014 to June&#160;2021, including serving as the Executive Chairman from 2014 to April&#160;2020, and as its Chief Executive
Officer from February&#160;2019 to April&#160;2020. Dr.&#160;Laumas has served as a director of Unicycive Therapeutics Inc. since 2018.
He began his career at Goldman Sachs &amp; Co. in New York in the Investment Banking Division. Dr.&#160;Laumas then joined Balyasny Asset
Management in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. He
has been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr.&#160;Laumas has served as a director of Parkway
Holdings Ltd. (IHH Healthcare) and SRL Ltd. Dr.&#160;Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from
Albany Medical College in 1995 with a research gap year at the Dana- Farber Cancer Institute and completed his medical internship in 1996
from the Yale University School of Medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Vimal Mehta, Ph.D.</i></b>,
62, co-founded the Company and has served as a member of our Board since April&#160;2017 and as our Chief Executive Officer and President
since May&#160;2017. Dr.&#160;Mehta also served as our Corporate Secretary from May&#160;2017 to February&#160;2021. He is also the co-founder
of BioXcel Corporation (now BioXcel LLC) and, following its inception in 2005 until March&#160;2023, served as its Chairman of the Board
and Chief Executive Officer. Dr.&#160;Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-Doctoral
Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr.&#160;Mehta has garnered a deep
understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives
encompassing corporate strategy and planning, global business development, and corporate fundraising.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Michael Miller</i></b>,
66, has served as a director of the Company since June&#160;2022. He has served as an advisor to several biopharmaceutical companies,
including Concarlo Therapeutics since June&#160;2022 and Rigel Pharmaceuticals, Inc. since January&#160;2022. Prior to that, he served
as Executive Vice President, Commercial of Jazz Pharmaceuticals plc from March&#160;2014 to August&#160;2020. Since May&#160;2018, Mr.&#160;Miller
has served on the Board of Puma Biotechnology Inc., where he also serves on the Compensation Committee. Mr.&#160;Miller received his B.S.&#160;from
the University of San Francisco and his M.B.A. from San Francisco State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Krishnan Nandabalan,
Ph.D</i></b>, 60,. co-founded the Company and has served as a member of our Board since May&#160;2017. Dr.&#160;Nandabalan served as a
consultant to the Company in the capacity of Chief Digital Officer from January&#160;2020 to August&#160;2022. He is also the co-founder
of BioXcel Corporation (now BioXcel LLC) and, following its inception in 2005, has served as its President, Secretary and Chief Scientific
Officer and as a member of its board of directors. Dr.&#160;Nandabalan has also served as Chief Executive Officer and a director of InveniAI
LLC, a wholly owned subsidiary of BioXcel LLC, since May&#160;2017 and as Chief Executive Officer and a director of Invea Therapeutics,
Inc. since October&#160;2021. Dr. Nandabalan holds a B.Sc. and M.Sc. in agricultural science from Tamil Nadu Agricultural University and
a Ph.D. in biochemistry and molecular biology from Indian Institute of Science.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Michal Votruba, M.D.</i></b>,
57, has served as a director of the Company since March&#160;2019. Since 2013, Dr.&#160;Votruba has been a Director of the Gradus/RSJ
Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Dr.&#160;Votruba
served as a director of Mynd Analytics, Inc., a telebehavioral health services company, from July&#160;2015 to 2019, and served as a director
of Telemynd, Inc., successor to Mynd Analytics, since 2019. Since 2010, he has served as a member of the board of PrimeCell Therapeutics
as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central
Europe. In 2009, the Czech Academy of Sciences solicited Dr.&#160;Votruba&#8217;s expertise for the first successful privatization project
of the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projects
in the Czech Republic. Dr.&#160;Votruba earned his M.D. from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter,
he emigrated from Czechoslovakia and developed his professional career in Canada and the USA. Since 2005, Dr.&#160;Votruba combined his
theoretical and clinical experience in the field of Competitive Intelligence serving the global pharmaceutical industry for eight years
as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli&#160;Lilly, Allergan, EMD, Serono and Sanofi.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following information with
respect to our executive officers is presented as of May 1, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><b>See above for Vimal Mehta&#8217;s
biography</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Richard I. Steinhart</i></b>,
66, has served as our Senior Vice President and Chief Financial Officer since March&#160;2018. From October&#160;2017 to March&#160;2018,
Mr.&#160;Steinhart served as our Vice President and Chief Financial Officer. From October&#160;2015 to June&#160;2017, he was Vice President
and CFO at Remedy Pharmaceuticals, Inc. From January&#160;2014 to September&#160;2015 Mr.&#160;Steinhart worked as a financial and strategic
consultant to the biotechnology and medical device industries. From April&#160;2006 through December&#160;2013, Mr.&#160;Steinhart was
employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April&#160;2006
to April&#160;2012 and as Sr. Vice President, Finance and Chief Financial Officer from April&#160;2012 to December&#160;2013. From May&#160;1992
until joining MELA Sciences, Mr.&#160;Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking,
venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures,
he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr.&#160;Steinhart&#8217;s other experience includes
seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General
Partner and Chief Financial Officer. Mr.&#160;Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc., a position
he assumed in November&#160;2013, and Atossa Genetics, Inc., where he began his service in March&#160;2014. Mr.&#160;Steinhart serves
as the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Corporate Governance Committees. Mr.&#160;Steinhart
serves as the Chairman of Atossa Genetics Audit Committee and is a member of its Audit Committee and Compensation Committee. He holds
B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Matthew Wiley</i></b>,
51, has served as our Senior Vice President and Chief Commercial Officer since January&#160;2022. Mr.&#160;Wiley has over 25 years of
sales, marketing, and strategy experience across multiple specialty product launches. Prior to joining the Company, Mr.&#160;Wiley served
as Chief Commercial Officer at VYNE Therapeutics, Inc., a therapeutics pharmaceutical company seeking to treat immuno-inflammatory conditions,
from November&#160;2018 to September&#160;2021, where he oversaw all the commercial buildout and objectives related to the launch of the
company&#8217;s first two approved dermatology products, AMZEEQ<sup>&#174;</sup> and ZILXI<sup>&#174;</sup>. Prior to that, he served as
Vice President and Business Unit Lead for Jazz Pharmaceuticals, Inc., a global biopharmaceutical company, from 2012 to 2018 where he led
the go-to-market strategy and marketing team for SUNOSI&#8482;, for narcolepsy and sleep apnea, and developed the successful growth strategy
for XYREM&#8482;, for narcolepsy, which achieved $1.4 billion in net revenue during his final year. He also served as Vice President of
Marketing at Azur Pharma, a specialty pharmaceutical company with a focus in central nervous system disorders, from 2007 to 2012, supporting
the company from initiation of U.S.&#160;operations through its acquisition by Jazz Pharmaceuticals. Mr.&#160;Wiley holds a B.A. from
Syracuse University in English.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Frank D. Yocca, Ph.D.</i></b>,
67, has served as our Senior Vice President and Chief Scientific Officer since March&#160;2018. From June&#160;2017 to March&#160;2018,
Dr.&#160;Yocca served as our Vice President and Chief Scientific Officer. From April&#160;2015 to April&#160;2017, he was Senior Vice
President, CNS R&amp;D of BioXcel. From 2005 to 2015, Dr.&#160;Yocca held multiple leadership roles at AstraZeneca plc, including Vice
President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, Strategy
Unit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Prior
to this, he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent
leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this, Dr.&#160;Yocca
served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation
of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer&#8217;s clinical
candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of
the Early and Late Discovery and Development Teams from 1984 to 2001. Dr.&#160;Yocca holds a B.S.&#160;in biochemistry from Manhattan
College and an M.S.&#160;in pharmacology and a Ph.D. in neuropharmacology from St. John&#8217;s University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Vincent J. O&#8217;Neill,
M.D.</i></b>, 54, has served as our Senior Vice President and Chief Medical Officer since March&#160;2018. From July&#160;2017 to March&#160;2018,
Dr.&#160;O&#8217;Neill served as our Vice President and Chief Medical Officer. He served as the Chief Medical Officer of Mirna Therapeutics,
Inc. from April&#160;2016 to May&#160;2017. From June&#160;2014 to May&#160;2016, he served as the Chief Medical Officer of Exosome Diagnostics,
Inc., a diagnostics company. From 2012 to 2014, Dr.&#160;O&#8217;Neill was global head of Personalized of Medicine and Companion Diagnostics
at Sanofi S.A., a pharmaceutical company. From 2009 to 2012, Dr.&#160;O&#8217;Neill served as Group Director at Genentech, Inc. where
he was involved in the expanded approval of products such as Avastin and Tarceva. From 2006 to 2009, Dr.&#160;O&#8217;Neill served as
Director, Discovery Medicine at GlaxoSmithkline plc. Dr.&#160;O&#8217;Neill holds an M.D., MBChd and M.Sc. in Pathology from the University
of Glasgow, UK.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Javier Rodriguez</i></b>,
51, has served as our Senior Vice President and Chief Legal Officer and Corporate Secretary since January&#160;2021. Javier has over 20
years of extensive strategic and legal experience within the biopharmaceutical industry and has broad leadership experience managing legal,
compliance, corporate governance, intellectual property, data privacy, and government affairs professionals. Prior to joining BioXcel
Therapeutics, he was Chief Legal Officer at Indivior PLC (LSE: INDV), a global pharmaceuticals company with operations in over 40 countries,
from December&#160;2014 to December&#160;2020, where he oversaw all legal affairs, data privacy compliance, and corporate governance matters.
Before taking on his role at Indivior, Javier was General Counsel at Reckitt Benckiser Pharmaceuticals Inc. where he played a key leadership
role in negotiating and successfully effectuating the demerger and spin-off of the organization in 2014, which included closing a $750
million secured term loan and $50 million revolving credit facility to fund on-going operations of the demerged entity. Earlier in his
career, Javier held roles of increasing responsibility at Reckitt Benckiser LLC, Bayer Healthcare Pharmaceuticals, Inc. and Berlex, Inc.
He began his legal career in 2000 as a litigation associate at Thelen Reid &amp; Priest, LLP in New York City. He holds a B.S.&#160;in
Civil Engineering from Rutgers University, a M.S.E. in Structural Engineering from the University of Michigan and a J.D. from the University
of Pennsylvania.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-style: normal">Corporate
Governance</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Audit Committee</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a separately-designated
standing audit committee whose current members are Peter Mueller, Sandeep Laumas, Michael Miller and Michal Votruba, with Dr. Laumas serving
as chair. All members of our audit committee meet the requirements for financial literacy under the applicable Nasdaq rules and regulations.
Our Board of Directors has affirmatively determined that each member of our audit committee qualifies as &#8220;independent&#8221; under
Nasdaq&#8217;s additional standards applicable to audit committee members and Rule 10A-3 of the Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;) applicable to audit committee members. In addition, our Board of Directors has determined that Dr. Laumas
qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Code of Business
Conduct and Ethics</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal
financial officer, principal accounting officer or controller or persons performing similar functions. A copy of our Code of Business
Conduct and Ethics is available under the &#8220;Governance&#8212;Governance Documents&#8221; section&#160;of the Investors page of our
website located at www.bioxceltherapeutics.com, or by writing to our Corporate Secretary at our offices at 555&#160;Long Wharf Drive,
New Haven, CT 06511. We intend to make any required disclosures regarding amendments to, or waivers of, provisions of our Code of Conduct
on our website rather than by filing a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span id="ss003"></span>Item 11.</td><td style="text-align: left">Executive Compensation</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">EXECUTIVE COMPENSATION</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a discussion
of the compensation arrangements of our named executive officers (&#8220;NEOs&#8221;). As an &#8220;emerging growth company&#8221; as
defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section&#160;and have elected to comply
with the scaled disclosure requirements applicable to emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our NEOs include our principal
executive officer and our two most highly compensated executive officers, other than our principal executive officer, for the fiscal year
ended December&#160;31, 2022. These NEOs and their positions are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">Vimal Mehta, Ph.D., our Chief Executive Officer and President;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">Javier Rodriguez, our Senior Vice President, Chief Legal Officer and Secretary; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">Matthew Wiley, our Senior Vice President and Chief Commercial Officer.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Summary Compensation
Table</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table shows information
regarding the compensation of our NEOs for the years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-size: 8pt"><b>Name and Principal
    Position</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Year</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Salary<br />
    ($)</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; text-align: center"><span style="font-size: 8pt"><b>Bonus<br />
    ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; text-align: center"><span style="font-size: 8pt"><b>Stock
    Awards<br /> ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; text-align: center"><span style="font-size: 8pt"><b>Option<br />
    Awards<br /> ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; text-align: center"><span style="font-size: 8pt"><b>Non
    Equity<br />
    Incentive Plan<br />
    Compensation<br /> ($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; text-align: center"><span style="font-size: 8pt"><b>All
    Other<br />
    Compensation<br /> ($)<sup>(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal"><span style="font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Total<br />
    ($)</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; font-size: 10pt; text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><span style="font-size: 8pt">Vimal
    Mehta, Ph.D</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 7%; font-size: 10pt; text-align: center"><span style="font-size: 8pt">2022</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">944,436</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">150,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">800,592</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">1,994,080</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">654,662</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">15,425</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 7%; font-size: 10pt; text-align: right"><span style="font-size: 8pt">4,559,195</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-style: italic; text-align: left; text-indent: -5.4pt; padding-left: 0.15in"><span style="font-size: 8pt">Chief
    Executive Officer</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 8pt">2021</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">916,701</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">7,964,625</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">483,052</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">7,800</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">9,372,177</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><span style="font-size: 8pt">Javier Rodriguez</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 8pt">2022</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">403,650</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">50,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">181,439</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">398,219</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">177,606</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">7,625</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">1,218,539</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-style: italic; text-align: left; text-indent: -5.4pt; padding-left: 0.15in"><span style="font-size: 8pt">Senior
    VP and Chief Legal Officer</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 8pt">2021</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">334,028</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">1,543,898</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">136,500</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">2,014,426</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><span style="font-size: 8pt">Matthew Wiley</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 8pt">2022</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">402,500</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">1,307,572</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">210,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">7,625</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">1,927,697</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-style: italic; text-align: left; text-indent: -5.4pt; padding-left: 0.15in"><span style="font-size: 8pt">SVP
    and Chief Commercial Officer</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table>





<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">The amounts reported reflect a one-time bonus paid to each of Dr.&#160;Mehta and Mr.&#160;Rodriguez in
recognition of the successful completion of a strategic financing for BTAI during 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">The amounts reported represent the grant date fair value of restricted stock units and stock options granted
to our NEOs as computed in accordance with Accounting Standards Codification 718, Compensation &#8212; Stock Compensation (ASC 718). Note
that the amounts reported in these columns reflect the accounting cost for these awards and do not correspond to the actual economic value
that may be received by our NEOs from the awards. We provided information regarding the assumptions used to calculate the value of the
restricted stock units and stock option awards in Note 11 to our financial statements included in our Annual Report on Form 10-K for the
year ended December&#160;31, 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">The amounts reported represent annual cash bonuses earned for 2022 and paid in 2023. For additional information,
see &#8220;2022 Annual Bonuses&#8221; below.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(4)</td><td style="text-align: justify">The amounts reported for 2022 represent reimbursement for healthcare benefits for Dr.&#160;Mehta ($7,800)
and 401(k) matching contributions ($7,625) for each named executive officer.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Narrative to Summary
Compensation Table</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2022 Salaries</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our NEOs receive a base salary
to compensate them for services rendered to the Company. The base salary payable to each NEO is intended to provide a fixed component
of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. The base salaries of our NEOs are reviewed
from time to time and adjusted when our Board or compensation committee determines an adjustment is appropriate. In early 2022, the Board
increased the base salaries of Dr.&#160;Mehta and Mr.&#160;Rodriguez to $944,436 and $403,650, respectively, in connection with annual
merit increases for all employees. Mr.&#160;Wiley&#8217;s annual base salary for 2022 of $420,000 was negotiated in connection with his
commencing employment in January&#160;2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2022 Annual Bonuses</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We offer our NEOs the opportunity
to earn annual cash bonuses to compensate them for attaining company and individual performance goals. Each NEO&#8217;s target bonus opportunity
is expressed as a percentage of annual base salary. The 2022 annual bonuses for Dr.&#160;Mehta, Mr.&#160;Rodriguez and Mr.&#160;Wiley
were targeted at 55%, 40% and 40%&#160;of their respective base salaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance goals for
annual bonuses are reviewed and approved annually by the compensation committee. For 2022, our NEOs were eligible to earn annual bonuses
based on the achievement of certain company performance goals, which generally related to clinical trial performance, and completing certain
financial and operational objectives, as well as an assessment of individual performance. In March&#160;2023, the Board approved the 2022
annual bonuses for the NEOs following an assessment of the NEOs&#8217; individual performance and the Company&#8217;s achievement against
company performance goals. The actual annual cash bonuses awarded to each NEO for 2022 performance are set forth above in the Summary
Compensation Table in the column entitled &#8220;Non-Equity Incentive Plan Compensation.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Equity Compensation</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2022, we awarded stock
options and restricted stock units to our NEOs as the long-term incentive component of our executive compensation program. We typically
grant equity awards at such times as our Board determines appropriate. The following table sets forth the equity awards granted to our
NEOs during 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><b>2022 Equity Awards Granted (#)</b></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><b>Name</b></td><td style="padding-bottom: 1pt; font-size: 10pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><b>Options</b></td><td style="padding-bottom: 1pt; font-size: 10pt"><b>&#160;</b></td><td style="padding-bottom: 1pt; font-size: 10pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><b>RSUs</b></td><td style="padding-bottom: 1pt; font-size: 10pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Vimal Mehta, Ph.D</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">167,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">56,750</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Javier Rodriguez</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">33,350</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">13,337</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Matthew Wiley</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The options were granted with
exercise prices equal to the fair market value of our common stock on the date of grant. The stock options and restricted stock units
generally vest over four years with 25% of the shares subject to the award vesting on the first anniversary of the date of grant and the
remaining 75% of the shares subject to the award vesting, with respect to options, in substantially equal monthly installments over the
following thirty-six months, and with respect to restricted stock units, in substantially equal quarterly installments over the following
12 quarters, subject, in each case, to the holder&#8217;s continued service through the applicable vesting date; provided that 15,000
restricted stock units granted to Dr.&#160;Mehta and 5,000 restricted stock units granted to Mr.&#160;Rodriguez in 2022 vest on the first
anniversary of the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Refer to the &#8220;Outstanding
Equity Awards at Year End&#8221; table below for additional information regarding the equity awards we granted to our NEOs during 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Other Elements of Compensation</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our NEOs are eligible to participate
in our employee benefit plans and programs, which generally include medical, dental and vision benefits, and life, short-term, and long-term
disability insurance to the same extent as our other full-time employees generally, subject to the terms and eligibility requirements
of those plans. During 2022, we reimbursed Dr.&#160;Mehta for his healthcare premium payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a 401(k) defined
contribution plan (the &#8220;401(k) Plan&#8221;), for the benefit of our employees who satisfy certain eligibility requirements. Our
NEOs are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. In 2022, we matched employee contributions
to the 401(k) Plan up to 50% of the first 5% of eligible compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts paid pursuant
to these arrangements are set forth in the Summary Compensation Table in the column entitled &#8220;All Other Compensation.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Outstanding Equity
Awards at Year End</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
all outstanding equity awards held by each of the NEOs as of December&#160;31,&#160;2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Vesting <br />
Commencement <br />
Date</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of<br />
 Securities<br />
 Underlying<br />
 Unexercised<br />
 Options (#)<br />
 Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of<br />
 Securities<br />
 Underlying<br />
 Unexercised<br />
 Options (#)<br />
 Unexercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option<br />
 Exercise<br />
 Price ($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option <br />
Expiration<br />
 Date</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of<br />
 Shares or<br />
 Units of Stock<br />
 That Have<br />
 Not
    Vested<br />
 (#)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Market Value<br />
 of Shares or<br />
 Units that <br />
Have Not<br />
 Vested ($)<sup>(1)</sup></b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 18%; font-size: 10pt; text-align: left">Vimal Mehta, Ph.D</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt; text-align: left">08/23/2017</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">414,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">0.41</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt; text-align: center">08/23/2027</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">05/23/2019</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">187,700</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">10.04</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">05/23/2029</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">05/26/2020<sup>(2)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">161,458</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">88,542</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">45.99</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">05/26/2030</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">03/25/2021<sup>(2)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">109,374</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">140,626</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">41.17</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">03/25/2031</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">03/14/2022<sup>(3)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">167,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">15.31</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">03/14/2032</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">03/14/2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#8212;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">41,750</td><td style="font-size: 10pt; text-align: left"><sup>(4)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">896,790</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">05/12/2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#8212;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">15,000</td><td style="font-size: 10pt; text-align: left"><sup>(5)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">322,200</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Javier Rodriguez</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">02/22/2021<sup>(2)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,666</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">17,334</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">54.90</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">02/22/2031</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">08/16/2021<sup>(2)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,333</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,667</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23.84</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">08/16/2031</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">03/14/2022<sup>(3)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">33,350</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">15.31</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">03/14/2032</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">03/14/2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#8212;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8,337</td><td style="font-size: 10pt; text-align: left"><sup>(4)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">179,079</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">05/12/2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#8212;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,000</td><td style="font-size: 10pt; text-align: left"><sup>(5)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">107,400</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Matthew Wiley</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">01/17/2022<sup>(3)</sup>&#160;</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">18.00</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">01/17/2032</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>





<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">The amounts shown are based on the closing price of our common stock on December&#160;30, 2022 of $21.48
per share.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">The unvested portion of the option vests in substantially equal monthly installments until the fourth
anniversary of the vesting commencement date.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">The option vests as to 25% of the shares on the first anniversary of the vesting commencement date and
in substantially equal monthly installments thereafter until the fourth anniversary of the vesting commencement date.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(4)</td><td style="text-align: justify">The RSUs vest as to 25% of the shares on the first anniversary of the vesting commencement date and in
substantially equal quarterly installments thereafter until the fourth anniversary of the vesting commencement date.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(5)</td><td style="text-align: justify">The RSUs vest on the first anniversary of the vesting commencement date.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Employment Arrangements</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into employment
agreements with each of our NEOs that set forth the terms and conditions of each executive&#8217;s employment with us. Each employment
agreement establishes an annual base salary and target bonus opportunity for each NEO. The amounts in effect during 2022 are described
above under the headings &#8220;2022 Salaries&#8221; and &#8220;2022 Annual Bonuses.&#8221; The NEOs are eligible to participate in our
employee benefit plans and programs for which the NEO is eligible, subject to the terms and conditions of such plans and programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2022, in the event
that an NEO was terminated by us without cause, or by the executive for good reason, subject to the NEO&#8217;s timely execution and non-revocation
of a release of claims in our favor, the executive would have been eligible to receive (i) a pro-rated portion of the executive&#8217;s
annual bonus for the year of termination; (ii) base salary continuation for 24 months for Dr.&#160;Mehta, 6 months for Mr.&#160;Rodriguez
or 9 months for Mr.&#160;Wiley; and (iii) reimbursement for COBRA premium payments for the applicable severance period. In addition, Dr.&#160;Mehta
would be entitled to vesting of 50% of any unvested equity awards held by him immediately prior to his termination. The Company must provide
an NEO 30 days&#8217; notice in the event we terminate such NEO without cause.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreements
also provide that, in the event an NEO&#8217;s employment is terminated by us without cause or by the NEO for good reason, in either case,
within 6 months prior to or 12 months after a change in control, then, subject to the NEO&#8217;s timely execution and non-revocation
of a release of claims in our favor, the NEO will be entitled to a lump sum payment equal to 6 months of base salary (or 24 months of
base salary for Dr.&#160;Mehta), which payment is in addition to the severance payments and benefits described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreements
generally define &#8220;cause&#8221; as, subject to certain notice and cure rights, the NEO&#8217;s (i) material breach or material default
of the employment agreement or any other agreement between us and the NEO, or repeated failure to follow the direction of the Company
or our Board, as applicable; (ii) gross negligence, willful misfeasance or breach of fiduciary duty to us or our affiliates; (iii) commission
of an act or omission involving fraud, embezzlement, misappropriation or dishonesty in connection with NEO&#8217;s duties to us or our
affiliates, or, for Mr.&#160;Rodriguez or Mr.&#160;Wiley, that is otherwise likely to be materially injurious to the business or reputation
of the Company or our affiliates; or (iv) conviction of, indictment for, or pleading guilty or nolo contendere to, any felony or other
crime involving fraud or moral turpitude.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreements
generally define &#8220;good reason&#8221; as, subject to certain notice and cure rights, the occurrence of any of the following (without
the NEO&#8217;s express written consent): (i) a significant reduction of the NEO&#8217;s duties, position or responsibilities, or the
removal of the NEO from such position, duties or responsibilities; (ii) for Dr.&#160;Mehta and Mr.&#160;Rodriguez only, the relocation
of the NEO by more than 25 miles; or (iii) any action or inaction that constitutes a material breach by us or any of our successors of
its obligations to the NEO under the employment agreement (or for Dr.&#160;Mehta, any other agreement between us and Dr.&#160;Mehta).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreements
also contain covenants prohibiting the NEOs from competing with us or soliciting our suppliers, employees or customers during employment
and for a period of one year following termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">DIRECTOR COMPENSATION</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The non-employee members of
our Board are eligible to receive compensation for their service on our Board. During 2022, our Board approved certain updates to our
director compensation program based on an analysis provided by Radford, the company&#8217;s independent compensation consultant, comparing
our director compensation levels to those of our peers. Under our director compensation program, during 2022 each non-employee director
was eligible to receive an option to purchase 30,000 shares of common stock upon such director&#8217;s initial election or appointment
to the Board. Additionally, each non-employee directors who has been serving as a non-employee director for at least six months as of
the date of any annual meeting of stockholders and will continue to serve as a non-employee director immediately following such meeting,
was eligible to receive an option to purchase 17,000 shares of common stock on the date of such annual meeting. The options granted to
our non-employee directors have an exercise price equal to the fair market value of our common stock on the date of grant and expire not
later than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vest in
three substantially equal annual installments following the date of grant. The stock options granted annually to directors vest in a single
installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested
stock options vest in full upon the occurrence of a change in control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, our non-employee
directors were eligible to receive cash retainers for service on our Board and committees of our Board during 2022 as set forth in the
table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Position</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt; text-align: justify">Base Board Fee</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">60,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify">Chair of Board or Lead Independent Director</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">35,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Chair of Audit Committee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">20,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify">Chair of Compensation Committee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">15,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Chair of Nominating and Corporate Governance Committee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">10,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify">Member of Audit Committee (non-Chair)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">10,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Member of Compensation Committee (non-Chair)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,500</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify">Member of Nominating and Corporate Governance Committee (non-Chair)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">5,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Director fees under the program
are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar
quarter, <i>provided </i>that the amount of each payment will be prorated for any portion of a quarter that a director is not serving
on our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also reimburse all of our
non-employee directors for all reasonable and customary business expenses in accordance with company policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Director Compensation
Table</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information for the year ended December&#160;31, 2022 regarding the compensation awarded to, earned by or paid to our non-employee directors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Name</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fees Earned or<br />
 Paid in Cash<br /> ($)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><b>Option Awards<br /> ($)<sup>(1)</sup></b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><sup>&#160;</sup>&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">All Other<br />
 Compensation<br /> ($)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Totals<br />
 ($)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Peter Mueller, Ph.D.</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">120,840</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">174,327</td><td style="width: 1%; font-size: 10pt; text-align: left"><sup>(2)</sup>&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">295,167</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Sandeep Laumas, M.D.</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">90,289</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">174,327</td><td style="font-size: 10pt; text-align: left"><sup>(3)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">264,616</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Krishnan Nandabalan, Ph.D.<sup>(7)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left"><sup>&#160;</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">100,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">100,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Michal Votruba, M.D.</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">68,421</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">174,327</td><td style="font-size: 10pt; text-align: left"><sup>(4)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">242,748</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">June Bray</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64,368</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">174,327</td><td style="font-size: 10pt; text-align: left"><sup>(5)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">238,695</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Michael Miller</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">19,194</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">336,057</td><td style="font-size: 10pt; text-align: left"><sup>(6)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">355,251</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>




<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">The amounts reported represent the grant date fair value of stock options granted to our non-employee
directors as computed in accordance with ASC 718. Note that the amounts reported in this column reflect the accounting cost for these
stock options and do not correspond to the actual economic value that may be received by the recipients from the options. We provide information
regarding the assumptions used to calculate the value of the option awards in Note 11 to our financial statements included in our Annual
Report on Form 10-K for the year ended December&#160;31, 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">As of December&#160;31, 2022, Dr.&#160;Mueller held options to purchase an aggregate of 232,597 shares
of our common stock, of which 215,597&#160;shares of common stock were exercisable.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">As of December&#160;31, 2022, Dr.&#160;Laumas held options to purchase an aggregate of 190,388 shares
of our common stock, of which 173,388&#160;shares of common stock were exercisable.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(4)</td><td style="text-align: justify">As of December&#160;31, 2022, Dr.&#160;Votruba held options to purchase an aggregate of 66,200 shares
of our common stock, of which 49,200&#160;shares of common stock were exercisable.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(5)</td><td style="text-align: justify">As of December&#160;31, 2022, Ms. Bray held options to purchase an aggregate of 46,167 shares of our common
stock, of which 12,499 shares of common stock were exercisable.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(6)</td><td style="text-align: justify">Mr.&#160;Miller joined the board in June&#160;2022. As of December&#160;31, 2022, Mr.&#160;Miller held
options to purchase an aggregate of 30,000 shares of our common stock, of which no shares of common stock were exercisable.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(7)</td><td style="text-align: justify">Dr.&#160;Nandabalan serves as President and Chief Scientific Officer of BioXcel Corporation and did not
receive compensation for his service on our board during 2022. Until August&#160;31, 2022, Dr.&#160;Nandabalan served as a consultant
to the Company in the capacity of Chief Digital Officer and amounts shown in the table above represent cash fees earned by Dr.&#160;Nandabalan
for his service to the Company in such role. See &#8220;Certain Transactions with Related Persons - Consulting Arrangements with BioXcel
LLC Employees&#8221; below for additional information. As of December&#160;31, 2022, Dr.&#160;Nandabalan held options to purchase 423,688
shares of our common stock, of which 423,688 shares of common stock were exercisable.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Compensation Committee
Interlocks and Insider Participation</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the 2022 fiscal year,
the members of our compensation committee were Drs. Laumas and Mueller, neither of whom was, during the fiscal year, an officer or employee
of the Company and neither of whom was formerly an officer of the Company. During 2022, none of our executive officers served as a member
of the board of directors or compensation committee (or other committee performing equivalent functions) of any entity that had one or
more executive officers serving on our Board or compensation committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal year ended
December&#160;31, 2022, no other relationships required to be disclosed by the rules of the SEC existed aside from those identified herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span id="ss004"></span>Item 12.</td><td style="text-align: left">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Security Ownership
of Certain Beneficial Owners and Management</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table sets forth
information relating to the beneficial ownership of our common stock as of April&#160;27, 2023 by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding
shares of common stock;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">each of our directors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">each of our named executive officers for 2022; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">all directors and executive officers as a group.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares beneficially
owned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a &#8220;beneficial&#8221;
owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct
the disposition of such security. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that
the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock
beneficially owned by them, subject to any applicable community property laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The percentage of shares beneficially
owned is computed on the basis of 29,159,638 shares of our common stock outstanding as of April&#160;27, 2023. Shares of our common stock
that a person has the right to acquire within 60&#160;days of April&#160;27, 2023 <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>are
deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding
for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors
and executive officers as a group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o 555 Long Wharf
Drive, New Haven, CT 06511.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Name of Beneficial Owner</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Number of Shares<br />
 Beneficially Owned</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font-size: 10pt; font-weight: bold">Percentage of Shares<br />
 Beneficially Owned</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Holders of more than 5%:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 70%; font-size: 10pt; text-align: left">BioXcel LLC<sup>(1)</sup>&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 14%; font-size: 10pt; text-align: right">8,546,750</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 14%; font-size: 10pt; text-align: right">29.3</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">FMR LLC<sup>(2)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,203,436</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14.4</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Adage Capital Advisors, L.L.C.<sup>(3)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,548,591</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5.3</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Named executive officers and directors:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Vimal Mehta, Ph.D.<sup>(4)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">962,722</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3.2</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Javier Rodriguez<sup>(5)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">40,325</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Matthew Wiley<sup>(6)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">30,104</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">June Bray<sup>(7)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">37,832</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Sandeep Laumas, M.D.<sup>(8)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">190,388</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Michael Miller<sup>(9)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Peter Mueller, Ph.D.<sup>(10)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">465,194</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1.6</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Krishnan Nandabalan, Ph.D.<sup>(1) (11)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8,850,438</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">30.0</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">Michal Votruba, M.D.<sup>(12)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">250,575</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">*</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">All executive officers and directors as a group:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">(12&#160;individuals)<sup>(13)</sup>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11,258,330</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">35.8</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  </table>




<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">*</td><td style="text-align: justify">Represents less than 1%.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(1)</td><td style="text-align: justify">Based on a Schedule&#160;13G/A filed with the SEC on April 4, 2023 and information known
to us, BioXcel LLC and BioXcel Holdings, Inc. have shared voting power and shared dispositive power over 8,547,750 shares of our common
stock. Dr.&#160;Mehta and affiliated trusts are significant stockholders of BioXcel Holdings, Inc. Dr.&#160;Nandabalan and affiliated
trusts are significant stockholders of BioXcel Holdings, Inc. Dr.&#160;Nandabalan also is a manager and officer of BioXcel LLC, and a
director, officer and stockholder of BioXcel Holdings, Inc. BioXcel LLC is majority owned and controlled by BioXcel Holdings, Inc. As
such, Dr.&#160;Nandabalan may be deemed to beneficially own the shares held of record by BioXcel LLC. The address of BioXcel LLC and BioXcel
Holdings, Inc. is 2614 Boston Post Road Suite 33B, Guilford, CT 06437.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(2)</td><td style="text-align: justify">Based solely on a Schedule&#160;13G/A filed with the SEC on February&#160;9, 2023, FMR LLC beneficially
owns 4,203,436 shares of our common stock, including sole voting power over 1,772,374 shares and sole dispositive power over 4,203,436
shares; Abigail P. Johnson has sole dispositive power over 4,203,436 shares and Fidelity Growth Company Fund has sole voting power over
1,772,374&#160;shares. The address for FMR LLC, Abigail P. Johnson and Fidelity Growth Company Fund is 245 Summer Street, Boston, Massachusetts
02210.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(3)</td><td style="text-align: justify">Based solely on a Schedule&#160;13G filed with the SEC on February&#160;2, 2023, Adage Capital Partners,
L.P. beneficially owns 1,548,591 shares of our common stock. Adage Capital Partners GP, L.L.C., Adage Capital Advisors, L.L.C, Richard
Atchinson and Phillip Gross each have shared voting power and shared dispositive power over 1,548,591 shares of our common stock. The
address for Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C., Adage Capital Advisors, L.L.C., Robert Atchinson and Phillip
Gross is 200 Clarendon Street, Boston, Massachusetts 02116.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(4)</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents for Dr.&#160;Mehta: (i) 17,894 shares of common stock (of
which 2,000 shares are owned jointly with Dr.&#160;Mehta&#8217;s spouse); (ii)&#160;options to purchase 927,219 shares of our common stock
that can be exercised within 60 days of April 27, 2023 and (iii) 17,609 RSUs that vest within 60 days of April 27, 2023.</p></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(5)</td><td style="text-align: justify">Represents for Mr.&#160;Rodriguez: (i) 1,134 shares of common stock,
(ii) options to purchase 33,670 shares of our common stock that can be exercised within 60 days of April 27, 2023 and (iii) 5,521 RSUs
that vest within 60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(6)</td><td style="text-align: justify">Represents for Mr.&#160;Wiley options to purchase 30,104 shares of our common stock that can be exercised
within 60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(7)</td><td style="text-align: justify">Represents for Ms. Bray options to purchase 37,832 shares of our common stock that can be exercised within
60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(8)</td><td style="text-align: justify">Represents for Dr.&#160;Laumas options to purchase 190,388 shares of our common stock that can be exercised
within 60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(9)</td><td style="text-align: justify">Mr.&#160;Miller does not beneficially own any shares of our common stock.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(10)</td><td style="text-align: justify">Includes for Dr.&#160;Mueller 90,000 shares of our common stock held by the Peter Mueller 2018 Irrevocable
Family Trust, as to which Dr.&#160;Mueller serves as trustee, and options to purchase 232,597 shares of our common stock that can be exercised
within 60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(11)</td><td style="text-align: justify">In addition to shares described in footnote (1), includes for Dr.&#160;Nandabalan options to purchase
303,688 shares of our common stock that can be exercised within 60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(12)</td><td style="text-align: justify">Includes 184,375 shares of our common stock held by RSJ Investments SICAV a.s. (&#8220;RSJ/Gradus&#8221;)
and over which Dr.&#160;Votruba, an asset manager at RSJ/Gradus, has voting and/or dispositive power. Also includes options to purchase
66,200 shares of our common stock that can be exercised within 60 days of April 27, 2023, which options Dr.&#160;Votruba was granted in
respect of his service on our Board but as to which he assigned to RSJ/Gradus pursuant to the policies of RSJ/Gradus regarding stock ownership
by employees.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 27pt">(13)</td><td style="text-align: justify">Includes (i) options to purchase 2,233,652 shares of our common stock
that can be exercised within 60 days of April 27, 2023 and (ii) 29,693 RSUs that vest within 60 days of April 27, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Equity Compensation
Plan Information</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
certain information with respect to the Company&#8217;s equity compensation plans in effect as of December&#160;31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Plan Category</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Number of securities<br /> to be issued upon<br /> exercise of <br /> outstanding options,<br /> warrants and rights<br /> (a)</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Weighted-average<br /> exercise price of<br /> outstanding options,<br /> warrants and rights<br /> (b)</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Number of securities<br /> remaining available for<br /> future issuance under<br /> equity compensation<br /> plans (excluding <br /> securities reflected in<br /> column (a))<sup>(4)</sup><br /> (c)</b></td><td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt; text-align: left">Equity compensation plans approved by security holders<sup>(1)</sup>&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: right">5,001,351</td><td style="width: 1%; font-size: 10pt; text-align: left"><sup>(2)</sup>&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">17.23</td><td style="width: 1%; font-size: 10pt; text-align: left"><sup>(3)</sup>&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right">1,223,219</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: justify">TOTAL</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">5,001,351</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">17.23</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,223,219</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">Consists of the BioXcel Therapeutics, Inc. 2017 Incentive Award Plan (the &#8220;2017 Plan&#8221;), the
BioXcel Therapeutics, Inc. 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) and the BioXcel Therapeutics, Inc. 2020 Employee Stock
Purchase Plan (the &#8220;2020 ESPP&#8221;).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">Includes 2,260,621 outstanding options to purchase shares under the 2017 Plan, 119,268 restricted stock
units and 2,621,462 outstanding options to purchase shares under the 2020 Plan.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">As of December&#160;31, 2022, the weighted-average exercise price of outstanding options under the 2017
Plan was $3.62 and the weighted-average exercise price of outstanding options under the 2020 Plan was $28.98. The weighted average exercise
price of outstanding awards does not take into account the shares issuable upon vesting of outstanding restricted stock units which have
no exercise price.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(4)</td><td style="text-align: justify">Includes 599,244 shares available for future issuance under the 2020 Plan and 623,975 shares available
for issuance under the 2020 ESPP. Following the effective date of the 2020 Plan, we ceased making grants under the 2017 Plan. To the extent
outstanding awards under the 2017&#160;Plan are forfeited or lapse unexercised, the shares of common stock subject to such awards will
be available for issuance under the 2020&#160;Plan. The 2020 Plan provides for an annual increase to the number of shares available for
issuance thereunder on the first day of each calendar year beginning on January&#160;1, 2021 and ending on and including January&#160;1,
2030, by an amount equal to the lesser of (i)&#160;4% of the aggregate number of shares of common stock outstanding on the final day of
the immediately preceding calendar year and (ii)&#160;such smaller number of shares of common stock as determined by our board of directors
(but no more than 10,000,000 shares may be issued upon the exercise of incentive stock options). The 2020 ESPP provides for an annual
increase to the number of shares available for issuance thereunder on the first day of each calendar year beginning on January&#160;1,
2021 and ending on and including January&#160;1, 2030, by an amount equal to the lesser of (i)&#160;1% of the aggregate number of shares
of common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;such smaller number of shares of
common stock as is determined by our board of directors, <i>provided</i> that no more than 500,000 shares of our common stock may be issued
under the component of the 2020 ESPP that is intended to qualified under Section&#160;423 of the Code.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span id="ss005"></span>Item 13.</td><td style="text-align: left">Certain Relationships and Related Transactions, and Director Independence</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Policies and Procedures
on Transactions with Related Persons</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors recognizes
that transactions with related persons present a heightened risk of conflicts of interests and/or improper valuation (or the perception
thereof). Our Board has adopted a written policy on transactions with related persons, which requires that our audit committee approve
or ratify related person transactions required to be disclosed pursuant to Item 404(a). Item 404 of Regulation S-K requires disclosure,
subject to certain exceptions, of transactions in which we were or are to be a participant and the amount involved exceeds $120,000 (or
such other amount is applicable while we remain a smaller reporting company) and in which any &#8220;related person&#8221; as defined
under Item 404(a) of Regulation S-K had or will have a direct or indirect material interest. It is our policy that directors interested
in a related person transaction will recuse themselves from any vote on a related person transaction in which they have an interest and
that no director may participate in the approval of a related person transaction for which he or she is a &#8220;related person.&#8221;
Each of the transactions described below entered into following the adoption of our related person transaction policy was approved in
accordance with such policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">BioXcel LLC</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BioXcel LLC owned approximately
29.3% of the shares of our outstanding common stock as of April 27,&#160;2023. BioXcel LLC is the successor in interest to BioXcel Corporation,
our former parent. BioXcel LLC is majority owned and controlled by BioXcel Holdings, Inc. Vimal Mehta and affiliated trusts are significant
stockholders of BioXcel Holdings, Inc. and was previously a member of the board of managers and an officer of BioXcel LLC and a director
and officer of BioXcel Holdings, Inc. Dr.&#160;Nandabalan and affiliated trusts are significant stockholders of BioXcel Holdings, Inc.
Dr.&#160;Nandabalan is also a manager and officer of BioXcel LLC, and a director, officer and stockholder of BioXcel Holdings, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: #231F20">Amended
and Restated Asset Contribution Agreement with BioXcel LLC</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into an asset contribution
agreement, effective June&#160;30, 2017, with BioXcel LLC (formerly BioXcel Corporation), as amended and restated on November&#160;7,
2017 (the &#8220;Contribution Agreement&#8221;), pursuant to which BioXcel LLC contributed to us, and we acquired from BioXcel LLC, all
of BioXcel LLC&#8217;s rights, title and interest in and to BXCL501, BXCL701, BXCL502 and BXCL702 (collectively, the &#8220;Candidates&#8221;)
and all of the assets and liabilities associated with the Candidates, in consideration for (i) 9,480,000 shares of our common stock, (ii)&#160;$1
million upon completion of our initial public offering (&#8220;IPO&#8221;), (iii) $500,000 upon the later of the 12 month anniversary
of our IPO and the first dosing of a patient in the bridging bioavailability/bioequivalence study for the BXCL501 program, (iv) $500,000
upon the later of the 12 month anniversary of our IPO and the first dosing of a patient in the Phase 2 Proof of Concept open label monotherapy
or combination trial with Keytruda for the BXCL701 program and (v) a one-time payment of $5 million within 60 days after the achievement
of $50 million in cumulative net sales of any product or combination of products resulting from the development and commercialization
of any one of the Candidates or a product derived therefrom. There were no such payments during the years ended December&#160;31, 2021
or 2022 pursuant to such provisions in the Contribution Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the
Contribution Agreement, BioXcel LLC granted us a first right to negotiate exclusive rights to any additional product candidates in the
fields of neuroscience and immuno-oncology (the &#8220;Option Field&#8221;) that BioXcel LLC may identify on its own, excluding the Candidates,
and not in connection with BioXcel LLC&#8217;s provision of services to us under the Services Agreement as defined and described below.
This first right to negotiate an exclusivity period expired on March&#160;12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Amended and Restated
Separation and Shared Services Agreement</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a separation
and shared services agreement, dated June&#160;30, 2017, or the Effective Date, with BioXcel LLC (formerly BioXcel Corporation), as amended
and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which services provided by BioXcel LLC through its subsidiaries
in India and the United States will continue indefinitely, as agreed upon by the parties. These services are primarily for drug discovery,
chemical, manufacturing and controls cost and general and administrative support. Service charges recorded under this agreement were $1.4
million for the years ended December&#160;31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Services Agreement,
the Company has an option, exercisable through December&#160;31, 2024, to enter into a collaborative services agreement with BioXcel LLC
pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing EvolverAI. The Company has agreed
to pay BioXcel LLC $18 per month, prorated for any partial month, as applicable, for the period beginning March&#160;13, 2023 and ending
December&#160;31, 2024 as consideration for the option. The parties are obligated to negotiate the collaborative services agreement in
good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty
on net sales and reasonable development and commercialization milestone payments, <i>provided </i>that (i) development milestones shall
not exceed $10 million in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestones shall
be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate.
BioXcel LLC shall continue to make such product identification and related services available to us for at least until September&#160;30,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Trademark License Agreement</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&#160;19, 2022, we
entered into the BioXcel Trademark License Agreement, pursuant to which BioXcel LLC granted us a royalty-free license to use the BIOXCEL
trademark in connection with marketing, promoting and selling any products and services in the field of neuroscience, for which the Company
paid BioXcel LLC a one-time fee of $135,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Consulting Arrangements
with BioXcel LLC Employees</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January&#160;2020 to
August&#160;31, 2022, Krishnan Nandabalan, Ph.D., a director on our Board, was engaged as a consultant in the capacity of Chief Digital
Officer. In connection with this service, Dr.&#160;Nandabalan was granted an option to purchase 15,000 shares of our common stock having
a value of approximately $142,800. In addition, in accordance with the Amended Services Agreement, the Company pays BioXcel LLC, where
Dr.&#160;Nandabalan serves as President, monthly compensation of $12,500 in an annual aggregate amount not to exceed $150,000 as consideration
under the Services Agreement for Dr.&#160;Nandabalan&#8217;s services as Chief Digital Officer, the full amount of which was paid for
the years ended December&#160;31, 2021. In the year ended December&#160;31, 2022, Dr.&#160;Nandabalan was paid $100,000 for his services
as Chief Digital Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">InveniAI</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">InveniAI, a wholly owned subsidiary
of BioXcel LLC, has agreed to provide certain research and development services to the Company in connection with our product candidates
up to a maximum aggregate amount of $300,000, $150,000 of which was paid in the year ended December&#160;31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Director and Officer
Indemnification and Insurance</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify
each of our directors and executive officers against certain liabilities, costs and expenses, and have purchased directors&#8217; and
officers&#8217; liability insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Director Independence</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Corporate Governance
Guidelines and Nasdaq rules, a director is independent if he or she does not have a material or other disqualifying relationship with
us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities as a director.
In addition, the director must meet the bright-line tests for independence set forth by the Nasdaq rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board has undertaken a
review of its composition, the composition of its committees and the independence of our directors and considered whether any director
has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her
responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and
affiliations, including family relationships, our Board of Directors has determined that none of Ms. Bray, Mr.&#160;Miller or Drs. Laumas,
Mueller or Votruba, representing five of our seven directors, has a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and that each of these directors qualifies as &#8220;independent&#8221; as
that term is defined under the Nasdaq rules. In making these determinations, our Board of Directors considered the relationships that
each non-employee director has with us and all other facts and circumstances our Board of Directors deemed relevant in determining their
independence, including the director&#8217;s beneficial ownership of our common stock and the relationships of our non-employee directors
with certain of our significant stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our Board of
Directors has affirmatively determined that each member of our Audit Committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s
additional standards applicable to audit committee members and Rule 10A-3 of the Exchange Act applicable to audit committee members. Our
Board has also determined that each member of our Compensation Committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s additional
standards applicable to compensation committee members and is a &#8220;non-employee director&#8221; as defined in Section&#160;16b-3 of
the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span id="ss006"></span>Item 14.</td><td style="text-align: left">Principal Accounting Fees and Services</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: #231F20">Audit,
Audit-Related, Tax and All Other Fees</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The table below sets forth the
aggregate fees billed to us for services related to the fiscal year ended December&#160;31, 2022 and 2021 by Ernst &amp; Young LLP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Year Ended December&#160;31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">2022</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">2021</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Audit Fees<sup>(1)</sup>&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,569,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">484,480</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Audit-Related Fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Tax Fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">All Other Fees</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left">TOTAL</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,569,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">484,480</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">Audit fees consisted of audit services performed in connection with the audit of the Company&#8217;s consolidated
financial statements, the reviews of the Company&#8217;s interim condensed consolidated financial statements, and related services that
are normally provided in connection with registration statements. Included in the 2022 and 2021 audit fees are $170,000 and $130,000,
respectively, billed in connection with our follow-on offerings. 2022 audit fees also include fees related to the audit and review of
the registration statements of the Company&#8217;s subsidiary, OnkosXcel Therapeutics LLC, of $904,200.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Pre-Approval Policies
and Procedures</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistent with SEC policies
and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit
services provided by our independent registered public accounting firm on a case-by-case basis. Our Audit Committee has established a
policy regarding approval of all audit and permissible non-audit services provided by our principal accountants. No non-audit services
were performed by our independent registered public accounting firm during the years ended December&#160;31,&#160;2022 and 2021. Our Audit
Committee pre-approves these services by category and service. Our Audit Committee pre-approved all of the above-described services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span id="bb1"></span>Item 15.</td><td style="text-align: left">Exhibits, Financial Statement Schedules</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Exhibits</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; width: 8%"><b>Exhibit<br /> Number</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
<td style="border-bottom: Black 1pt solid; width: 36%"><b>Description</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>Form</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>File No.</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>Exhibit</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>Filing Date</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>Filed/<br /> Furnished<br /> Herewith</b></td></tr>
<tr style="vertical-align: top">
<td style="text-align: left"><a href="tm2313834d1_ex31-1.htm" style="-sec-extract: exhibit">31.1</a></td>
    <td>&#160;</td>
<td style="text-align: left"><a href="tm2313834d1_ex31-1.htm" style="-sec-extract: exhibit">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: center"><a href="tm2313834d1_ex31-1.htm" style="-sec-extract: exhibit">*</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: left"><a href="tm2313834d1_ex31-2.htm" style="-sec-extract: exhibit">31.2</a></td>
    <td>&#160;</td>
<td style="text-align: left"><a href="tm2313834d1_ex31-2.htm" style="-sec-extract: exhibit">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: center"><a href="tm2313834d1_ex31-2.htm" style="-sec-extract: exhibit">*</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: left">104</td>
    <td>&#160;</td>
<td style="text-align: justify">Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document.)</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: left">&#160;</td>
    <td>&#160;</td>
<td style="text-align: center">*</td></tr>
</table>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: left">Dated: May 1, 2023</td>
<td colspan="2" style="text-align: left"><b>BIOXCEL THERAPEUTICS, INC.</b></td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: left; width: 50%">&#160;</td>
<td style="width: 2%">By:</td>
<td style="border-bottom: Black 1pt solid; width: 48%">/s/ Vimal Mehta&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: left">&#160;</td>
<td colspan="2" style="text-align: left">Vimal Mehta, Ph.D.</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: left">&#160;</td>
<td colspan="2" style="text-align: left">Chief Executive Officer</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: left">&#160;</td>
<td colspan="2" style="text-align: left">(<i>Principal Executive Officer</i>)</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>




















</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5ltpGRembFi1iFSkivga7lWCbLZv4dyRvaWwRl4VlmflmhBiIjFa6RobTosjhgE1bK4dQYIWM5ozeka43Cfhb4EVbx8q47v2BKXkGPTMJ45nyQme9a4tlAtF4KKdDOYJYJqMpzLci+OopmUqXaJxWNShTwp6pZY1O8atPOKgnGWpeXdUR2WoyCcRh1MtvkFEsYUd39SC+WsjzVASDbgKRMd3ab83NOmpgWWPju2yP/jf4ABZMSUU= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tm2313834d1_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Vimal Mehta, Ph.D., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 4%">1.</TD>
    <TD STYLE="text-align: justify; width: 96%">I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, of BioXcel Therapeutics,&nbsp;Inc.; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 1, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Vimal Mehta</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vimal Mehta, Ph.D.</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




















</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tm2313834d1_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Richard Steinhart, certify that:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 4%">1.</TD>
    <TD STYLE="text-align: justify; width: 96%">I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, of BioXcel Therapeutics,&nbsp;Inc.; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top; width: 96%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 1, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Richard Steinhart</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Steinhart</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>btai-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaGabOdzZR+2YkxtmB9bYlKfywop65jjiNpC8oWwZ0K -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:BTAI="http://bioxceltherapeutics.com/20221231" elementFormDefault="qualified" targetNamespace="http://bioxceltherapeutics.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://bioxceltherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="btai-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="btai-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>btai-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>btai-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://bioxceltherapeutics.com/role/Cover" xlink:href="btai-20221231.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://bioxceltherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140068190558784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioXcel Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1386754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Long Wharf Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-6837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,888,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,009,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Stamford, Connecticut<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2313834d1_10ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="btai-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001720893</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-38410</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">BioXcel Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">82-1386754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">555 Long Wharf Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">475</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">238-6837</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">BTAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-12-31">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">250888981</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-13" decimals="INF" unitRef="Shares">29009536</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Stamford, Connecticut</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +& H58'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "Q@*%6<.#OB>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R''H8";-I:.G#@8K;.QF;+4UBQUC:R1]^SE9FS*V!]C1TN]/
MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,B=\;A[ZZ!3E9SQ"4/I#
M'1$$Y_?@D)11I& "%F$ALK8Q6NJ(BOIXP1N]X,-G[&:8T8 =.O24H"HK8.TT
M,9S'KH$;8((11I>^"V@6XES]$SMW@%V28[)+:AB&<JCG7-ZA@K>GW<N\;F%]
M(N4UYE_)2CH'7+/KY-=Z\[C?LE9P41=\5?!J+[CD*RD>WB?7'WXW8=<;>[#_
MV/@JV#;PZR[:+U!+ P04    " "Q@*%6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M +& H59=IJP'H0<  .\Q   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MM<]HX%(7_BH;M=-J9$/P"A+0),\0D6[9IR@;:;G9G/RBV $]LBY5EDOS[
MO38&XXQ\P3/B2X.QS\%Z*EGWV/+%,Q=/\8(Q25["((HO&PLIEY]:K=A=L)#&
MIWS)(M@SXR*D$C;%O!4O!:->)@J#EF48W59(_:C1O\B^&XO^!4]DX$=L+$B<
MA"$5KU<LX,^7#;.Q^>+>GR]D^D6K?[&D<S9A\L=R+&"KM77Q_)!%L<\C(MCL
MLC$P/PW;1BK(COCIL^=XYS-)F_+(^5.Z,?(N&T9Z1BQ@KDPM*/Q9,8<%0>H$
MY_%?;MK8_F8JW/V\<;_)&@^->:0Q<WCPR_?DXK+1:Q"/S6@2R'O^_(7E#>JD
M?BX/XNQ?\KP^MF,TB)O$DH>Y&,X@]*/U7_J2@]@1M,T*@94+K#<"LUTAL'.!
M?:B@G0O:&9EU4S(.0RII_T+P9R+2H\$M_9#!S-30?#]*_]\G4L!>'W2R[_ 5
M$Z1)?DR&Y,.[CQ<M":;IKI:;&URM#:P* ],BWW@D%S&YCCSFE0U:<#;;4[(V
MIW1EH8Y#YIX2VSPAEF%9BA-R</DW*DZ):6=R6R$?XO(_D@A^W5#]>JDU]A:P
MG?G9*.!_!H^Q%-#)_U417CNTU0[IR/\4+ZG++ALPM&,F5JS1?_^;V34^J^CH
M-!MJ,BN1:V_)M3'W_I"["5QA))F^+ID*&RXWC>;7UD!%"-75):3)K$2HLR74
M09LX #Q>AN@FH',5(EP_HT&L(NN@LKJ$-)F5"'6WA+J']:%!%"4T(/=LR854
MD<)]I$B4H%!575":S$J@SK:@S@X<;(+"I)[-R=6P<*_*;H7*ZM+29%:BU=O2
MZAU&:\R$S[UTZB,P_2JO4GN<-I-=Y6R'ZNM"TV16@G:^A79^&+0;/W9A+.;L
M;N#K6 4.=[MY4,%"-75A:3(KP3*-HC S:N%Z8%14P]IC5M6Y<%E=8+K<RL1V
M2ED3;:23"/$6&#8R]]@UFZ;5M$TE-E19&YLFMS(VJ\!FH>V\CJ0O7X%:P,A=
M$CXRH82%FQB&V;1[;=-0XD*UM7%I<BOC*NIY$RUZ-[CNV=Q/2WKH;W<T5/<O
MW.C*YW^Y+"#3!1-TR1+IN_$)&47NJ9*AUKI>EUN985'9FWAMGC-T8+0*&*DC
M2(XOY"M[55+$K0SH>6>6T3M793T'%]>F=HQBWRRJ?1,OUW-J4_I"1AZ@\V>^
M2[-*#1FVN&7/:IIVKWO6:2OI:<T!NMS*](HD8.(E?$X/QA<74-=FX$[(1,+D
M0+@@#D^@,T*?Y)YZ,.\)&M=*@%KS@2ZW,L B(9AX69\#''@>N,.5*O] ;N$X
M\CU24\,M.YT.N>71G/Q:4#$C0^&OE,$!MZG-\1C1P2RR@XF7_&\Y.ND6], I
M?XZ4#'&[._9,OM 54VD=7%L;W#'B@UGD!Q,O^=^"VX[=L> K/W+5/1#W=*9*
M;%ISA"ZW\MW4(DA8>.W_%MN8QQ(FW;_]9>7%;H^CT>V8RKH8U]7EILNMS*V(
M$]:>.)%1$XQ68\(-VF<=)22MX4&76QE2$1XLO.Z_Y5F47_ ("P][3"R[U^SV
M[#,E+:W909=;F5:1'2R\Y)_Z$D(6GQ'3^O#XD4R8FPCH94IDN)/#PQ *OXGD
M[M,)64+27=$@8>2=<0H%,5DR06*84Y6S*6Y=&^DQHH151 D+K_^G@GH^5!"3
MU_"1!TJ2N,'5=#!24M(:'72YE2D5T<'"Z_Q-3R/7+^Z"1G-6&5KW&-T-)L/!
MGTI>6L."+K<RKR(L6 >%A5\L")I/$11F,%9I#!<YCXSB.*FXRN&>=UR)36M$
MT.56QE9$!.N@B/"3!Q"FJ%C?5!+*&Y9[G"I@:<T!NMS*L(H<8!V4 S9W+==/
M6[)+&=2UZKN\>QP?F$KEX*K:U(X1 JPB!%@'A8!1))E8+QI)[^_2#48E-=RQ
MBIK6#*#+K;P&H<@ ]D$9(!N.Q('8-.="67;L\;GC49.Z+@,;,/'6ALI5"%J3
M@"ZW,KTB"=AX(9_3FX0T",A5$L/N6#D^]_A4/47&9;5A'2,1V$4BL ]ZG' =
M,C%/KV:_@X-<0(8*ES12]SG<L)*:UF2@RZU,;6>5T)ZG"NE".!A0=UR2*2<_
M8D;D@D&Y)EFZK&KWL?SZN:D2)/X;E2#U+ADZ1AZPBSQ@'_1H8;* T@WM=+A-
MY1H&7%<;UC%B@5W$ ON@)PKCY#'P77(3<*J<0'&7V@O4M :%W*V3N:6K7%=]
MJV/T>KWSGGG16JGP%"G /B@%E+/V)(W5,?F>R%C2*,V>2F0ZRWHG=^ON-O+<
M,,X[=G?;QAS',0* 700 &R_;1\[-/1DDGB^Y( ,I&3#*+EI5"]3V^%4/0ZU)
M0)=;F5J1!&R\;M\ J\KD>^37(HHE>4_#Y6?RP!.8<V]OQTIH6H. +K<RM"((
MV'C9OH&6WH%,NY@2'&X!02N<<>&=P!"/HG0ENINH+H .[E,;W#&R0+O( FV\
MAM^ N_%%2$9#%;<]#FWE6B)<5'M=K=:2O[6S0CXM3+,W#6+BI@]]UXOEM]]N
MWV889&OX6\7AZU<AOM&TKHU)P&8@-4[/8.H1Z[<+UAN2+[/U]H]<2AYF'Q>,
M>DRD!\#^&>=RLY'^P/8=C_[_4$L#!!0    ( +& H5:R]\)O[@(  (D.   -
M    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*\8=HX4Q)_'FQJMCV R%P3H*[8=]
M*THL.P)9\F2Y<_KKI[,<YZ6ZLO7#ULTAD72/[IY'I[-$DD9O.+U94ZJ]KN*B
M6?AKK>L/0="LUK0BS5M94V&00JJ*:#-49=#4BI*\ :>*![/)) HJPH2?)J*M
M+BO=>"O9"KWPIZ/)L\WGW!BC=[YGPV4RIPO_[O3U]U;JBU>>;4_>G)Q,[LXN
MCNVG/7#F!VD2#$1I4DBQXPM]:S"LI*+>/>$+/R.<+14#KX)4C&^L>0:&E>12
M>=HLE()88VD>+#RU(\C!$*=B0JJ>VS+8W^4P_0C8CD @XWP4./.M(4UJHC55
MXM(,^LF]\1'D#?W;36T4EHILIK/W_LZA;PS)4JJ<JH.\6U.:<%J ',7*-;1:
MU@& 6LO*=')&2BE(KV'K,71,V!7E_ 8*Y%MQ$+LK]O9S KLIQJX1-'1M&#N
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( +& H59PX.^)[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( +& H5:97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ L8"A
M5EVFK >A!P  [S$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( +& H5:R]\)O[@(  (D.   -
M      "  >0/  !X;"]S='EL97,N>&UL4$L! A0#%     @ L8"A5I>*NQS
M    $P(   L              ( !_1(  %]R96QS+RYR96QS4$L! A0#%
M  @ L8"A5JK$(A8S 0  (@(   \              ( !YA,  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( +& H58D'INBK0   /@!   :
M  "  485  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M +& H59ED'F2&0$  ,\#   3              "  2L6  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  '47      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>37</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2313834d1_10ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioxceltherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  tm2313834d1_10ka.htm 25</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K/A" original="tm2313834d1_10ka.htm">tm2313834d1_10ka.htm</File>
    <File>btai-20221231.xsd</File>
    <File>btai-20221231_lab.xml</File>
    <File>btai-20221231_pre.xml</File>
    <File>tm2313834d1_ex31-1.htm</File>
    <File>tm2313834d1_ex31-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2313834d1_10ka.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 37
   },
   "contextCount": 3,
   "dts": {
    "inline": {
     "local": [
      "tm2313834d1_10ka.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btai-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btai-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btai-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 63,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 0,
   "keyStandard": 37,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "BTAI",
   "nsuri": "http://bioxceltherapeutics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2313834d1_10ka.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://bioxceltherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2313834d1_10ka.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bioxceltherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-23-054337-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-054337-xbrl.zip
M4$L#!!0    ( +& H5;9X8<B0P,  !8,   1    8G1A:2TR,#(R,3(S,2YX
M<V2U5FU3XC 0_GPW<_\AUZ].*,73$P0=7T:'$?5&?/]R$]H%HR&I22IXO_Z2
MM 6$BH!W_91NGN?9W61WV_KNL,_0"TA%!6]X0:GL(>"AB"CO-;RK-MYK'S2;
M'MK=^?85F:?^'6-T1(%%-70H0MSD7;&-SD@?:N@8.$BBA=Q&UX0EUB*.* .)
M#D0_9J#!;*2>:FBC%&P1A/$"NM? (R&O+IHCW0>M8U7S_<%@4.+BA0R$?%*E
M4/07$VQKHA,U4BL/R]FS&/V4JG!$7B-[&X.?PPMZVP.^E;3(^GUX0\@QZ9Q'
M?^XOUBIW3T/=WZ]V[MA)]W4@XLV-QT=Z%A]LB9O!??DD=5E7X0/T"3*7P57#
ML_EEZ0W62T+V_$JY'/BWIZVVPWDIL#9DE#\5P8-JM>J[W1PZ@QQV),NEUWV[
MW2$*1LIFE\[!4ZXTX>$;?*1'A$GPAI]NOH'20NAF"J4Y-((IG(*PU!,OOMDP
M^$KP_".')@KW"(E'\"Y1'2>;;3@X+@=X/<@I2NI9N#$60[%^C4$5$M*M MK^
MY5YSQ.A0,0R!Z0?3)#$DFH:N9"VM$E0L"1CT@>LC(?N'T"4),_$])X31+H7(
M0YK('FA;@RHF(2PNG-<TX5R8TC?]EUFL+8ZIJ6UC^%*W15"3@L&ER0?9A6FZ
M#]U8G'\@S SQ$(T:7KJT@D;>24;0I9PZOUFC!0C;MDILNF;I*'5_&CPAD2B(
MSOF.6\<2E.&Y1%K&D!$SR#NDD+ P8<MQQJ$44C)#?F#C(\R;Z0*ZR#5AS19(
MPU/4CD$OLSU(Z#:\CB84YS?UVZ16,J630ZSTG"9T)S]]&IGC7(+(<$9E9D@8
M$1&#U-14\<0D2$.GVM)_3;A!UH_RD/\O4F:DLVS*A@+L/^;:LOJ326:]XH^;
M)7N?;JBZ25=(C?A,D\X;H>GP;XG02<VAV#><\[ UX:!BYDUIJ*)QI,L$,3Z!
MY8+(>2L$\>X@+XI O4^P2YPN%W4]]Z,PUWTATS?34.46/-9:)9S93\@GXG%B
M*P3TYK(C+7TK9*7+5J<R)ZB/F.Y=K50BH4BXEJ\NPP6+9)*2O[CC6/IFIG\'
M%KN4G)5>B/U#^$1Q%/]@K!K(^Z51]U--L_P+4$L#!!0    ( +& H5;^F2CT
MB0L  &F/   5    8G1A:2TR,#(R,3(S,5]L86(N>&ULS9UA;^.V&<??#]AW
M8+TW&W".XV0KEO32(N>+"Z-IDL6YZ[9B*&B)<83(8DK)B?/M1XJB+%)\)"7#
M2-Z+.Y_Y?Z@_]?PL4A)%??QAMTG1,V%Y0K.ST?3@<(1(%M$XR=9GHR_+\?ER
MMEB,4%[@+,8IS<C9**.C'[[_XQ\0__/QF_$8S1.2QJ?H,XW&B^R>?H>N\(:<
MHA])1A@N*/L.?<7I5GQ#YTE*&)K1S5-*"L(+Y(9/T=\.IG_':#P>4.]7DL64
M?;E=U/4^%,53?CJ9O+R\'&3T&;]0]I@?1'0SK,)E@8MM7M=VN#NL_LCPCVF2
M/9Z*OU8X)XCOKRP_W>7)V4ALM]KLR_$!9>O)T>'A=/+/GR^7T0/9X'&2B?T6
MD9&*$K78XJ8G)R>3LE1)6\K=BJ5J&\<39:>NF9<F'?J&DSPYS4M[ES3"19GV
MWLT@4"'^-U:RL?AJ/#T:'T\/=GD\4CN_W(.,IN26W*.RF:?%ZQ-'*4\$":/J
MNP=&[NUF4L8F(GZ2D34N2"PV="(V-/U6;.A/U=>7>$72$1)*S@?8KA.MKBIH
MXMKL#6$)C2^R][DVHSW9Y[\=5OP/#6C&.V_"'2UP^B[SS4CGMJ_(^_;X/L[]
MGN;'>?*^/=V(_+_8+MJ6W[Q[[?LU%5]>\D^:1;(K> =&8F525-%Q!"ZW4'8,
M5=UU[332ZDW%T9RR=MM%SUC6F9/H8$V?)S%)>-U'T]__*CZ.Y<>RZ?R_O\TH
M'PV<K_*"X:A0M95-.1M9RB>F+:$\9\H;9E%/ RO%)**\>WHJQJG<E3+\GM&-
M=;-5RZFE\+=T5<?+7<,W 1C59(SD=,LB\J;,--U">ZERM$FY0@RK2#;^LAQ]
M7VK0KTKUGX^3?2V.DLV'0ML-R8H[7JNE%7JQJU3;3*E,-\N"2+3%D)EG)4%"
MXR')YWSCL3 P3_':T@2CW%6:K;94GK7"(!)M<V1FNM8@(?*9ZL\DCUCR)(;W
M76W19,X3;S'9RG]#$Q8&;6,P#0VMQX/\+5DGHJL1-L0Y+Q%?=AS2 +WK;J#3
MMMDO6,5!@#/$(=AS-(-0'>61I?,LV^+TECQ1UH60+G--CLVD"4Q3$Q0G%F,@
M'E*+I-@C%?_8\K-YPM+77C!:2M=L %9-/ Q94(38O8&0U'+_G-PQG.6).)CU
M@M*6.C\- <RV3DD,75"L .;@4Y5:[Y^6Y0-)4W'/ &?]!Q:;V#4QL&&3F;8R
M*&I >R W902J0L)"Y^)9C-KYT&E@@QMZGP"U;'<Q5(N#Q<AT.)"D,@R).(\T
M-6Y9]'#44KHF"+!JLF/(@J+&[@WD1<I1J0\#E(LL'H1)K?,#B6'3CD@E"A 0
MW5D?'ESM&XYYDD<XE7[F_+N\HXD6K6M(0+LF*"UA4+! [D!@9(#BI@SQ#LV_
M"&;#D&DH_0#3LFK'I98%"(OIK0\5H?<&RFS+F.8<[GU@J;.;N3UFZ_NZ@"X(
M6'K,M>[V2KD&B\?>Z"(KDN)5S,>[VFY6A%D:V):XX@,RI[@PRX/@ 3!E<B!E
M2.B0%'K+OKJKD!5B(B38)%/FE@*[29T$71,0#59C !%[;3DOU1L5,WZ48CA=
M9#'9_41>P;:U=&ZY &SJ8!BB@,BP.P/0J,2H5",N]P;'#4LVF+TNDZBGVV@+
MW>(!&=7Y,%4! 0)8 PBIU&BYF/GN5>[P;A%S8)/[1,XO[R$%U+L%IL>VS@T@
M#@B?;H< 13P(Z5&^85ID$65/M#%=8D:W_&#X.J,Q/&+IB7(+UJ FZ'AUA@0$
MV1"? &I:Z <YIP51\6Q060$2-7BC[CR.^<[*JW\NDXQ,P7U@U;HEK,.NSI5%
M&!!-L#N H4KY07U (@9=9R&!<_2&YA[Y!^=H*#A'08-S]!YP[EYH0. <OZ&Y
MQ_[!.1X*SG'0X!R_"QR>?._'G!G_>,WNZ(MMPC>H]()-VZH5FKTL/&1:WOJ
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M5Y?\$_]:?<7_6N&<\&_^"U!+ P04    " "Q@*%6-RY[!*D'  !:7@  %0
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MK34TT..4<'Z9:2:H#O8S>T(H:,2YMK76T$!?I53-;"?W0<FEF6_6GX: >QI
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M=^;=>W9Z3/_XNUQM_?VY_6/U^.=6ZQ+^!U?%MK?G_;I6^1M7_?>4U?ZM5_N
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M5%,[$8/KJ,V?Y[]R$B9G89>AYX< $0M<V),N^D<5MZ@QUX/3L6EN,;?'@H'
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M( 8Z8W:K"M6J*TQYSC(8"!])/%)$NM%HJ#MC+GSZ!YB[P/,\V"@#^#N0Y"]
M0D"21]>LO-O EG%_"')+.93,-.1?9?=M)>S,5/]MD%O<DV)<][Q&DB)X;SF9
MB8PZOGNN+.[G9_=&[0@U1,;?-6)@60/:"DZ)(ZJ3-5"X4@PRW7?W5X-%?F>-
M56J9QBJ5.1JK3&M(N$)M4Q8H-_(NL"$>3_X\.?I\??KEA!U=G%V>G+=;UZ<7
MYR\(T,M)L<R]37DIWN^&Y-F.;EUWDTG\W/-0#Y3L1C$4;-YMYMWJW%2L_/SD
M0G/J+9 420V.O)#47T&F!2;2-:7>5BPD=#4$Y]>+PS:JH6!3"#).'#>(6226
MR):>59+)"<B/HY7)K 9=-CXE.F2L =8@,#(@QR.O]ECUUJ%D1CC-*6Z<-D?2
M:G'^ C'K9 68YC/.C)85TD&T/2D=IEB8(!^9Y@LO8:XN5@1G ZL_L,<Q/>82
MG:$N2I'XNE=/B@L1X*92LBA6#T3[)QT1J<FKR-42NI/!2J:EJ+OREA?=.")S
M>14:)#U"'*Z0)-0^WEQI6"Y5&_GNLAY6OAF_8^WQ$!@VX62_]CYRD-TG'R?K
ML1KSETE]_[)R=+W?#]_O;%#=F!XY-Z:&S2/]_SW^N2:"UT8$J3M&,RA@YD6B
MU>H]^ PZ:SL<#M'F36I8Q<(UKORM:M+SEC^1A] ?N+=^NC=C;+%/:-5*D2:E
M0JLD,ITFJHKRXG4^EL1<5#26<J%'OGC']+]2?&<CV[([OS=T3G/G^Z*]$Y':
M218Q+2R[3ZRN<X!!5Z4,1.HL0G&IE$),U)K"CR9FU[VHHWCJK+BP!D#O5'J:
MQ:)"1K;OA^4O(-L9"\Y9W\3$CUWPL^,52!5__FFCNO&L.&YS&YCOAX['=A0T
MFS]LK2#2Z8=;JLZE@]@KO!.YT#YF>PY=)_2SNX,71#<K6_*FZ!/W*A?6]08N
M; /;@=O]*F%KW6*D56YFO(_5]3Z^AGV4S0B2)W&]G:]X.\]1BT;(3OX-K2 E
M_T[I9A Z9RYMGMKQ5*@CL^^U];Z_AGUOV4JAOD#/[KR;6W]EF[NR^_B8+;MV
MP=I?$045O3)S68]@C (N^AY6TT>#U/7>,:_?V:R6ZT:UMF]4&XVM' M3F:G5
MRH]S6),94WN[4:HG-Q]?><?HQWO62\YJ"4O"8ST%O]J2GH3PGEDT2F=8E6KL
MO?M6/Q?I8(CEP6MXL,T^N:KGQ=5SK>'>/?&0J=TS4;->-^JUW?6NK-2N5!IE
MHUPNKW=EI79EOUPV&LTU!UNM7:D8S6;=*.^O3\MJ[<MNHV[L[JY/RVKM2J5A
MU*N-]::LU*;4C4:C:52:+[,O3[*@_AA8@<@QF_+M;'JH@\6/-)_*I<J47('$
M,BF4K]Q)V<R>^4SVIU/B0NRERKP.AD72]O.B8L'0/L(&JNP:>^4UII>/:777
M8XWI-:;?#*;WC.8N:+I3E:HUKA>'Z_I^S2@WIMD4:TPODJKWI_J?UGA>H.YA
MU/:J1F5O[_EPO>R(R;T@+RQ*,EDW;05(ZJF1D/7I6J"\*->,W<::CRT?TS,#
M%FM$+P[1E?V*4:\UUYA>.J9K31!QE36FGX&F]_:,W?*T(/0:TXM4Z]>&ZK-0
M-'".?:/QG'SZ+;KQY5T]"=67RVD%CE>"Y-8._=4Y?;5:W2A7]]>87KN9UYA>
M8_K!LKM1KQG[S37_> 9<UW:-QMIOL.8?;PC350,; =2KSVC/OAV7?J8I\ K0
MT]J?OSI'JUZNKL7%6ERL,;W&]*,4^UIYSVCLK3GU,RA!E75 \'DPO7;I/Q?W
M:%8!U\W7DJFSJB[]+Y<2I%D5]U:"XN92_!]/<^OC]T U:8WH-:+7B%XC>HWH
M-:+7B%XC^BTB.M+X$W6F]?_-MMU45:0G:TC'(V=K"M_[85[C5>PNMZT[=R8[
MB"9'J^'Z,^/1;[I^4N/'C8.</JWT\<PJ54E,85M1]=]D6]$4A(]=\>LNK[XQ
M09V9TNI4G33]1I)<5?<)6>Z:#[%M&':APEY0 MLH]K!C"N/,=<1V  L$P],)
ML?>615U4J$$B]OSS5$=EJEHE>T7JGZ)K&LRB>ME=M^]8ND V=5Z)>G'+KBQ"
M/^0L;C6O&IYABV778X?7K5-FAM1RF1IXQ,?HP[I$_\)IJ/HD&E+5SFFO^QZ'
M?YG88PU[S;,;;H?4MPS>"3R+NO/X6*B5A4 DLAF+_-L=R58L- )V/%5-VV3/
M%I]()PQD1R%L@.>9U%2.^ONTXH9X[:C/YI%K6CW $%';7F7?2'<64OYY1F5C
MTX\V6^TC_&*KQ,Y=[-M+'0"#O-7+]D;8@-6UPZ'C1T>*WH[!ZF(K'%4D'M[F
MM[(5**S>=*D7$BQ(]F2G<R>_#D+L?]-U'7<()X10J6 9\C'K8 >CKK!N (S.
M.%&*7O<=EY-0?SKJ)V<2O%%M>Y8N;<]]/QRJ/0A]U42)VUULJBGHC6@OJ<?H
MG!NJEXH=VP&7K%+1W?CB%H=^ %/(-DRJSQ A%E]J.0XB(=.]KE+>_DUCLUC
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M%U=@,I]=GIRW6]>G%^??99P R1K-GLCK/*3,%LEF(AUOPG&M?2U$R8X?NS^
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M[SFFPZ3C;06UB9<.'5;*Z]CAWCIVN *DG*=\RFE3;"$K-V+]"X2VF*8'<G\
M?Z#ZAN(5A76>#JB2$(9#]!Y(>1<_2R5G^(G4$QF& /9-L:L.V..WRV(TTW'T
M/*EJBBMT0?3PD0_TKO^5RF+;F.^N7,X]N/NXCH1T;E-G\L+'I7+&Y-T5><#
M.0WFI]Q_ 00A"_EIH[KQ#(O4]Y%:E%JTY$4N_5:D(JG]O?OZ'D>IB8>HL\KC
M^E&(*?F.2VX$/7%-=>Z&WKJ*77FQO>F?O[A M!]' U33@8W*/0&V^TEP$_2\
MV*H]5MQ[)6\/UQ9QH?)%+P]/;D4K!%&*<1<IY582[]7<(_ *Z?XHZ419;9P_
MNKKY"M/ZN2L=R>B[ =7NR/5&+F9=L9]= ,NA(.^*[\HK/PEGY*_-X3ML$[5X
MVJF):P=KS"_V/,2;D,^/5GXO]HS&VS@$#V)(*[\M"Y48"[D#]#2K^3F3H:/
M 3H:XJBX"K04"QC2&O$QV?'HF/4\\DNCTQ-]$C/OVSENP))>;7+!]H"BG&!
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M;D"> 7I) .8!"U0,M+H)&!QX4N"<?O;36H\@GXAL2LP6;HN3-FDLBN"0A+%
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M]E?H3)3R);]V\<W"=4NWM31=Y)%<DINT9DI-3E<T][M:R8L,E#TDYA!QLB!
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M//Y#>R70P[CM-OFLW1^ ;A>H*V0G3<SSWO1G<>[>5,\'BL<(_P!02P,$%
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MVT>V?7TOW^?M:__?4$L! A0#%     @ L8"A5MGAAR)# P  %@P  !$
M         ( !     &)T86DM,C R,C$R,S$N>'-D4$L! A0#%     @ L8"A
M5OZ9*/2)"P  :8\  !4              ( !<@,  &)T86DM,C R,C$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( +& H58W+GL$J0<  %I>   5
M  "  2X/  !B=&%I+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " "Q@*%6
MO<ZPX\)]   DJP, %               @ $*%P  =&TR,S$S.#,T9#%?,3!K
M82YH=&U02P$"% ,4    " "Q@*%6T/X3KX@#  !-$   %@
M@ '^E   =&TR,S$S.#,T9#%?97@S,2TQ+FAT;5!+ 0(4 Q0    ( +& H5;0
M32J5D ,  /T/   6              "  ;J8  !T;3(S,3,X,S1D,5]E>#,Q
<+3(N:'1M4$L%!@     &  8 CP$  'Z<      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
